Clinical efficacy and safety of nicorandil for chronic ischemic cardiomyopathy patients with heart failure
10.3969/j.issn.1006-5725.2016.15.038
- VernacularTitle:尼可地尔对慢性缺血性心肌病合并心力衰竭患者的临床疗效及安全性研究
- Author:
Weisheng HUANG
;
Senhua LUO
;
Weixiang LUO
- Publication Type:Journal Article
- Keywords:
Nicorandil;
Chronic ischemic cardiomyopathy;
Heart failure
- From:
The Journal of Practical Medicine
2016;32(15):2544-2547
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical efficacy and safety of nicorandil in the treatment of chronic ischemic cardiomyopathy patients with heart failure. Methods The chronic ischemic cardiomyopathy patients with heart failure in our hospital were divided into two groups according to the random number table method. Control group underwent conventional anti heart failure treatment and symptomatic supportive treatment , and treatment group was treated by the nicorandil in addition to above treatments. After treatment for 6 months , comparisons of clinical efficacy and safety between two groups were conducted. Results The improvement of heart function in observation group was better than that in control group (Z = -2.302, P = 0.021). After treatment, the LVEF, 6 min walking distance were greater than those before treatment, and the LVESD, LVEDD were less than those before treatment (P < 0.05). The LVEF, 6 min walking distance in observation group after treatment were greater than those in control group and the LVESD , LVEDD were less than those in control group (P < 0.05). The incidence rate of adverse reaction in observation group was 9.59%, and 6.94% in control group, without statistical difference between two groups (χ2 = 0.334,P = 0.563). Conclusion In addition to conventional anti heart failure treatment , nicorandil can significantly improve the curative effect and the heart function in the treatment of chronic ischemic cardiomyopathy patients with heart failure and there are no significant adverse reactions. In addition , patients are tolerant.
